Negative in Ames, human lymphocyte chromosome aberration and rat bone marrow micronucleus assays
“Fostemsavir was not genotoxic in the bacterial reverse mutation assay (Ames test in Salmonella and E. coli), a chromosome aberration test in human lymphocytes, and rat bone marrow micronucleus test.”
2-year rat and 26-week transgenic mouse: no statistically significant tumor increases
“In a 2-year carcinogenicity study conducted in rats and a 26-week carcinogenicity study conducted in transgenic mice, fostemsavir produced no statistically significant increases in tumors over controls.”
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat EFD: cleft palate and other craniofacial malformations at maternally toxic 1,000 mg/kg/day
“Teratogenic effects occurred in rats at the maternally toxic dose of 1,000 mg/kg/day, such as cleft palate, open eyes, shortened snout, microstomia, misaligned mouth/jaw, and protruding tongue (SF =144).”
“Fostemsavir was not genotoxic in the bacterial reverse mutation assay (Ames test in Salmonella and E. coli), a chromosome aberration test in human lymphocytes, and rat bone marrow micronucleus test.”
Chromosome aberration test in human lymphocytes: negative
“Fostemsavir was not genotoxic in the bacterial reverse mutation assay (Ames test in Salmonella and E. coli), a chromosome aberration test in human lymphocytes, and rat bone marrow micronucleus test.”
“Fostemsavir was not genotoxic in the bacterial reverse mutation assay (Ames test in Salmonella and E. coli), a chromosome aberration test in human lymphocytes, and rat bone marrow micronucleus test.”
“The carcinogenic potential of orally administered FTR was assessed in a 2-year study in rats as well as in a 6-month study in CByB6F1/Tg rasH2 hemizygous mice.”
2-year rat and 26-week transgenic mouse completed before the marketing application; no significant tumor increases
“Fostemsavir produced no statistically significant increases in tumors over controls in a 2-year carcinogenicity study conducted in rats and a 26-week carcinogenicity study conducted in trnnsgenic mice.”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative